Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

This study is testing a combination of two blood cancer drugs — orelabrutinib and rituximab — as the first systemic treatment for people with a type of slow-growing lymphoma called marginal zone lymphoma (MZL), including MALT, splenic, and nodal subtypes. **You may be eligible if...** - You are 18 or older - You have histologically confirmed CD20-positive marginal zone lymphoma with a lesion larger than 1.5 cm outside the spleen - Your MZL has progressed or come back after local treatments (such as radiation, surgery, or antibiotic therapy for H. pylori), or local treatment is not appropriate - You have a medical reason to start systemic treatment (e.g., symptoms, low blood counts, or risk of organ damage) - Your performance status is ECOG 0–2 **You may NOT be eligible if...** - You have previously received systemic chemotherapy or immunotherapy for this lymphoma - You have active, uncontrolled infections or severe liver/kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.